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Abstract
Background: Mutation in the UPF3B gene on chromosome X is implicated in neurodevelopmental disorders
including X-linked intellectual disability, autism and schizophrenia. The protein UPF3B is involved in the
nonsense-mediated mRNA decay pathway (NMD) that controls mRNA stability and functions in the prevention
of the synthesis of truncated proteins.
Results: Here we show that NMD pathway components UPF3B and UPF1 are down-regulated during differentiation
of neural stem cells into neurons. Using tethered function assays we found that UPF3B missense mutations
described in families with neurodevelopmental disorders reduced the activity of UPF3B protein in NMD. In neural
stem cells, UPF3B protein was detected in the cytoplasm and in the nucleus. Similarly in neurons, UPF3B protein
was detected in neurites, the somatic cytoplasm and in the nucleus. In both cell types nuclear UPF3B protein was
enriched in the nucleolus. Using GFP tagged UPF3B proteins we found that the missense mutations did not affect
the cellular localisation. Expression of missense mutant UPF3B disturbed neuronal differentiation and reduced the
complexity of the branching of neurites. Neuronal differentiation was similarly affected in the presence of the NMD
inhibitor Amlexanox. The expression of mutant UPF3B proteins lead to a subtle increase in mRNA levels of selected
NMD targets.
Conclusions: Together our findings indicate that, despite the down-regulation of NMD factors, functional NMD is
critical for neuronal differentiation. We propose that the neurodevelopmental phenotype of UPF3B missense
mutation is caused by impairment of NMD function altering neuronal differentiation.
Keywords: Autism, Schizophrenia, X-linked intellectual disability, Nonsense-mediated mRNA decay, UPF3B mutation,
UPF1, Tethered function assay, qPCR, Arhgap24, Atf4, Protein localisation
Background
Mutation in the UPF3B gene located on chromosome
Xq24 has been implicated in X-linked intellectual dis-
ability (XLID), autism and schizophrenia. Nonsense and
missense mutations in UPF3B have been found in several
families with syndromic and non-syndromic XLID
(Table 1, Fig. 1a, Additional file 1: Figure S1) [1–6]. Several
subjects in these families also display autistic features. In
addition, mutation in UPF3B is described in schizophre-
nia [5]. Nonsense mutations introduce a premature
termination codon, leading to a loss of UPF3B expression,
most likely because they turn UPF3B mRNA into a target
for nonsense-mediated mRNA decay (NMD) [2, 3]. The
effect of missense mutations, which cause amino acid sub-
stitutions, upon UPF3B activity is not yet understood.
UPF3B protein acts in the NMD pathway which has im-
portant dual roles in prevention of synthesis of truncated
proteins and in regulation of gene expression. NMD
targets transcripts in which translation is arrested at a
premature termination codon for degradation (for review
see [7, 8]). Transcripts containing premature termination
codons arise for example from genes with nonsense muta-
tions or are produced by alternative splicing [9, 10]. In
addition, NMD has an important function in regulating
the expression of genes with specialised regulatory fea-
tures such as mRNA upstream open reading frames or
long 3’ untranslated regions. Further to its role in NMD,
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Loss of UPF3B protein function does not fully abolish
NMD activity. Vertebrates have a second UPF3 gene
termed UPF3A (Additional file 1: Figure S1). The con-
tribution of UPF3A to NMD in the presence of UPF3B
appears to be minor and is poorly understood [12].
However in cells lacking UPF3B protein, UPF3A protein
levels are elevated and the low level of selected NMD
substrates is maintained [13], indicating that UPF3A
protein is at least in part able to compensate for a loss
of UPF3B protein. In patients with UPF3B nonsense mu-
tation the lack of UPF3B expression is therefore most
likely due to the action of the UPF3A protein.
Normally, in situations that lead to NMD UPF1 is
recruited together with the peptide release factor
eRF3 to a ribosome stalled at a premature termination
codon. UPF3B and UPF2 regulate UPF1 function [14].
UPF3B interacts with the exon junction complex (EJC), a
protein complex deposited at exon joints, and with UPF2.
UPF2 and/or UPF3B then interact with UPF1 at the
stalled ribosome, and these interactions are important for
the regulation of UPF1 activity [15–17]. UPF2 promotes
phosphorylation of UPF1 by the kinase SMG1, leading to
the recruitment of mRNA decay factors and resulting in
mRNA degradation.
The missense mutations described in patients with
neurodevelopmental disorders are located within protein
domains of unknown function. UPF3B interacts with
UPF2 via an N-terminal RNP fold located between
amino acids 52–137 (Fig. 1a) and the EJC complex inter-
action domain in UPF3B has been mapped to amino
acids 421–434 [16, 18, 19]. The missense mutations in
UPF3B shown in Table 1 are not in these regions but
are located in highly conserved parts of the protein
(Fig. 1a, Additional file 1: Figure S1). Tyr160 is conserved
in vertebrate and fly UPF3B proteins, human UPF3A
and the C. elegans UPF3 homologue Smg-4. The other
amino acids affected, Arg255, Arg355 and Arg366 lie in
regions conserved from mammals to birds. The mutations
lead to non-conservative amino acid changes of Tyr160 to
Asp, Arg355 to Gln and Arg366 to His while the Arg255
to Lys substitution is a conservative amino acid change.
UPF3B protein is implicated in neuronal development.
In cells depleted of UPF3B by RNAi-mediated gene
knockdown or in lymphoblastoid cell lines from patients
with mutations in UPF3B the expression of genes involved
in neuronal development is de-regulated [13, 20]. Recent
findings link NMD to neuronal differentiation and axon
guidance [21, 22]. For example, knockdown of UPF3B in
cultured hippocampal neurons affects the expression of
NMD targets and alters neuronal outgrowth [21]. It is
notable that in addition to UPF3B, other NMD genes
including UPF2 and SMG6 have been implicated in
neuro-developmental disorders [23].
Here we demonstrate using tethered function assays
that missense mutations associated with neurodevelop-
mental disorders alter the function of UPF3B protein in
mRNA metabolism. Using Green Fluorescent Protein
(GFP)-tagged UPF3B proteins, we exclude a change in
cellular localisation as a mechanism. UPF3B and UPF1
protein are down-regulated upon induction of neuronal
differentiation of neural stem cells. Expression of mutant
UPF3B proteins that subtly affect the mRNA levels of
selected NMD substrates disturbs neuronal differenti-
ation, specifically the branching of neurites. Neurite
branching was similarly disturbed by exposure to the
NMD inhibitor Amlexanox. This work indicates that
despite the down-regulation of NMD factors, neuronal
differentiation relies critically on fully functional NMD
machinery. It contributes to our understanding of the
effect of UPF3B missense mutations in patients and
Table 1 UPF3B mutations linked to neurodevelopmental disorders
Mutation Open Reading Frame Phenotype UPF3B protein
Family 1 [2] 674_677delGAAA1 Arg225fs*201 FG syndrome (MIM 305450), subjects with autistic features
Family 2 [2] 867_868delAG1 Gly290fs*21 Lujan-Fryns syndrome (MIM 309520)
Family 3 [2] 1288C > T1 Arg430*1 Lujan-Fryns syndrome, subjects with autistic features
Family 4 [2] 478 T > G1 Tyr160Asp1 non-syndromic XLID, subjects with autistic features UPF3B-Asp160
Family T13 [3] 1081C > T2 Arg361*2 non-syndromic XLID
Family S98 [3] 1103G > A1 Arg368Gln1 Lujan-Fryns syndrome,also diagnosed as borderline ID with autism UPF3B-Gln3552
Family N37 [3] 1136G > A1 Arg379His1 non-syndromic XLID UPF3B-His3662
1 Family [1] 683_686delAAGA Gln228fs*18 Childhood onset schizophrenia, ASD, ADHD
1 Family [4] c697_698delAG Arg233fs*30 Developmental delay, ASD
1 patient [5] 764G > A1 Arg255Lys1 schizophrenia UPF3B-Lys255
1 Family [6] 1288C > T1 Arg430*1 non-syndromic XLID
1Location of mutation based on UPF3B transcript variant 1/isoform 1 (GenBank:NM_080632; GenBank:NP_542199). 2Location of mutation based on UPF3B
transcript variant 2/isoform 2 (GenBank:NM_023010; GenBank:NP_075386). Note that transcript variant 1 starts to deviate from transcript variant 2 at nucleotide
808, and isoform 1 from isoform 2 at amino acid 269. This difference is due to skipping of an exon (808–846) in the NM_080632 open reading frame
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Fig. 1 Missense mutations impair UPF3B activity in NMD. a. Schematic representation of UPF3B protein structure with location of protein-protein
interaction domains and amino acid changes. N-terminal N peptide and HA tag sequences are not shown. b. Schematic representation of the
tethering assay mimicking NMD. λNUPF3B protein is tethered to Renilla luciferase mRNA with BoxB elements in the 3’ UTR expressed from
phRL-TK-10BoxB (Test RNA) but is unable to bind mRNA expressed from phRL-TK lacking BoxB elements (Control RNA). Co-transfected
pGL3-promoter or phrGFP serve as standards in dual luciferase and qPCR assays, respectively (Reference). c. Expression of λN-HA-UPF3B proteins.
HeLa cells were transfected with pCI-λN-HA-UPF3B expression constructs and lysed after 48 h. Expression of UPF3B proteins and α-tubulin was
analysed by 10 % SDS PAGE followed by Western blotting with anti-HA and anti-tubulin antibodies. d, e. Tethering assay: Luciferase activity. Hela
cells were transfected with phRL-TK (d) or phRL-TK-10BoxB (e), together with reference plasmid pGL3-promoter and the pCI-λN-HA-UPF3B
expression constructs. Luciferase activities were measured 48 h after transfection. Renilla luciferase activities were standardised with respect to
firefly luciferase activity, and the activity in cells expressing UPF3B-Ala423 was defined as 1. Shown are average Renilla luciferase activities from
three independent experiments. f, g: Tethering assay: Luciferase mRNA levels. HeLa cells were co-transfected with phRL-TK (f) or phRL-TK-10BoxB
(g) but with phrGFP instead of pGL3-promoter. RNA was prepared 48 h later and mRNA levels were determined by qPCR. Luciferase mRNA levels
were standardised with respect to GFP mRNA levels, and luciferase mRNA in cells expressing UPF3B-Ala423 was defined as 1. Shown are average
luciferase mRNA levels from four independent experiments. Error bars indicate standard deviations, asterisks indicate values significantly different
from luciferase activity or mRNA levels in the presence of UPF3B (one-way ANOVA followed by Dunnett's test; P < 0.05).
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indicates that inhibition of the NMD pathway considered
for the treatment of genetic disease caused by nonsense
mutations may affect the development and function of
neuronal networks.
Results
Missense mutations affect UPF3B function in mRNA decay
Several independent missense mutations in UPF3B
have been reported in patients with neurodevelop-
mental disorders (Fig. 1a, Table 1). We wished to deter-
mine whether these mutations contribute to the disorders
by affecting the function of UPF3B protein in mRNA
metabolism. Tethered function assays (Fig. 1b) involving
the artificial binding of a protein to mRNA are an estab-
lished tool for the analysis of the function of NMD
factors in living cells. Using this approach it has been
shown previously that tethering UPF3B to mRNA leads to
the destabilisation of the target mRNA [11, 24] and that
interactions with UPF2 and exon junction complex
components are important for the function of UPF3B
in NMD [11, 18].
Tethering assays were performed in HeLa cells by
expressing N peptide-UPF3B fusion proteins and
Renilla luciferase mRNA with 10 BoxB RNA elements
located in the 3’ untranslated region (Test RNA, expressed
from phRL-TK-10BoxB). UPF3B is tethered to the
reporter mRNA by the highly specific interaction between
N peptide and BoxB elements in the mRNA (Fig. 1b).
Control reactions to identify any effects of UPF3B that are
not directly linked to its tethering to Renilla mRNA were
performed with Renilla luciferase mRNA that lacks the
BoxB elements and is therefore unable to bind to N
peptide-UPF3B fusion proteins (Control RNA, expressed
from phRL-TK).
The effects of missense mutations on UPF3B protein
function was examined by comparing the activities of wild
type UPF3B protein, of the 4 variants UPF3B-Asp160,
UPF3B-Lys225, UPF3B-Gln355, UPF3B-His366 identified
in patients with neurodevelopmental disorders (Table 1)
and of UPF3B-Ala423 with the synthetic inactivating
mutation Arg423Ala that was shown previously to be
inactive in tethered function assays [18]. The proteins
were expressed at similar levels in HeLa cells (Fig. 1c).
Tethered function assays were performed by transfection
of HeLa cells with the plasmid expressing either Test
or Control Renilla luciferase mRNA and a plasmid
for UPF3B protein expression. In addition, cells were
transfected with pGL3-promoter expressing firefly luciferase
as a reference, to allow for comparison between different
transfections. The assays with Control Renilla mRNA in
Fig. 1d show that expression of the Renilla luciferase
mRNA lacking the BoxB elements was largely unaffected by
the sequence differences between the UPF3B proteins, with
Renilla luciferase activities varying from the control up to
35 %. In tethering assays performed with Test Renilla
luciferase mRNA with BoxB sequences, Renilla luciferase
activity was highest when the inactive form UPF3B-Ala423
was tethered. For presentation in the graphs this was
defined as 1 (Fig. 1e). Tethering of wild type UPF3B caused
an approximately ten-fold reduction of Renilla luciferase
activity, reflecting the earlier observation that tethering of
UPF3B protein, but not UPF3B-Ala423 protein causes the
mRNA to decay [18]. Tethering of UPF3B proteins found
in patients with neurodevelopmental disorders resulted in
three- to five-fold higher Renilla luciferase activity than
when wild type UPF3B protein was tethered. This indicates
that the function of these proteins in NMD is impaired.
To examine directly the effect of the mutations on the
ability of UPF3B protein to control mRNA levels we
compared Renilla luciferase mRNA levels using a reverse
transcription/qPCR approach. Experiments were performed
in HeLa cells as described above, except that phrGFP-C
expressing GFP was used as a reference instead of pGL3
promoter. The expression of the various UPF3B proteins
did not affect the levels of the Control Renilla luciferase
mRNA significantly (Fig. 1f). Tethering of wild type
UPF3B protein to Test Renilla luciferase mRNA led to an
approximately 20-fold reduction of mRNA compared
to when UPF3B-Ala423 protein was tethered (Fig. 1g).
Significantly, tethering of the other UPF3B proteins
led to six- to ten-fold higher luciferase mRNA levels
than when wild type UPF3B was tethered. Together, these
experiments demonstrate that mutations in UPF3B linked
to neurodevelopmental disorders impair the activity of
UPF3B protein in NMD.
Downregulation of NMD factors UPF3B and UPF1 during
neuronal differentiation
We wished to examine the effect of the expression of
mutant UPF3B proteins on neuronal differentiation. We
decided to use HCN-A94 rat neural stem cells as a
model system. These cells have maintained the ability to
form neurons when grafted into adult brain and can be
induced to differentiate into neurons in vitro [25, 26].
Figure 2a shows that the induction of neuronal differen-
tiation leads to the expression of the neuronal marker
β-III Tubulin. Expression of β-III Tubulin in unin-
duced cells (day 0) was below the level of detection
by Western blotting, but was detected from day 2 onward,
confirming the neuronal differentiation of these cells.
Neuronal differentiation was reflected also in the forma-
tion of neurites that increased in complexity over time
(see Fig. 5). We examined the expression of NMD
factors UPF1 and UPF3B during the differentiation
process (Fig. 2a). The levels of both proteins decreased
rapidly after induction of differentiation and were at be-
tween 10 % and 20 % of the levels in undifferentiated cells
after seven to eight days of differentiation. We observed
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also a reduction of UPF3B mRNA levels during differ-
entiation (Additional file 1: Figure S2). In conclusion,
UPF1 and UPF3B are down-regulated during neuronal
differentiation.
Localisation of UPF3B and UPF1 in neural stem cells
We examined the cellular localisation of these proteins by
staining neural stem cells with anti-UPF1 and anti-UPF3B
antibodies. In replicating cells, UPF1 was found in the
cytoplasm. UPF3B on the other hand was detected in the
cytoplasm and nucleus where it was enriched in small
dots (Fig. 2b). A more detailed analysis of UPF3B nuclear
localisation revealed that the nuclear signal was generally
diffuse but concentrated in the nucleoli detected by
staining with anti-Fibrillarin antibody (Fig. 2d). After eight
days of neuronal differentiation, cellular distributions of
Fig. 2 NMD factors UPF1 and UPF3 localise to neurites while protein levels are downregulated during neuronal differentiation. a. Neural stem
cells were differentiated by the addition of forskolin and retinoic acid. Protein samples were prepared before (day 0 (d 0)) and at the indicated
time (d, days) after induction of differentiation. Equal amounts of protein were subjected to 8 % SDS PAGE and analysed for β-III Tubulin, UPF3B
and UPF1 protein levels by Western blotting. Samples were probed for GAPDH protein as loading control. Proteins with faster mobility indicated
by asterisk reflect the behaviour of UPF1 and UPF3B and are likely to be alternate isoforms. The relative changes of UPF3B and UPF1 protein levels
were quantitated using GAPDH as reference, with levels at day 0 defined as 1. The mobility of relevant molecular mass markers is indicated.
b. UPF1 and UPF3B protein localisation in undifferentiated HCN-A94 cells. Cells were stained with DAPI (blue) and with either anti-UPF3B antibody
(red) or anti-UPF1 antibody (green) were analysed by confocal microscopy. Shown are separate channels and merged images from a single section.
c. UPF3B and UPF1 localisation in neurons. Neural stem cells differentiated for 8 days and then stained with DAPI and either anti-UPF3B antibody or
anti-UPF1 antibody were analysed by confocal microscopy. Shown are separate channels and merged images from a single section through the
nucleus and 3 days renderings of corresponding Z-stacks. The scale bars represent 20 μm. Note that UPF3B and UPF1 are detected in neurites and
UPF1, but not UPF3B, largely is excluded from the nucleus. d. Nucleolar localisation of UPF3B. Undifferentiated or for 8 day differentiated neural
stem cells were stained with anti-UPF3B antibodies, anti-Fibrillarin antibodies and DAPI and then analysed by confocal microscopy. Sections shown
focus on the nuclear compartment. The scale bars represent 20 μm. Note that UPF3B is enriched in nucleoli stained by anti-Fibrillarin antibodies
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UPF1 and UPF3B were similar to undifferentiated cells:
UPF1 was detected in the somatic cytoplasm and through-
out the neurites while UPF3B was detected in the somatic
cytoplasm, in neurites and in the nucleus, where it was
enriched in nucleoli (Fig. 2c, d).
Differentiating neural stem cells are competent for
UPF3B-promoted NMD
We wished to determine whether differentiating neural
stem cells maintain the ability to mediate UPF3B-promoted
NMD, and whether this would be sensitive to mutations in
UPF3B. First we determined that the proteins were
expressed similarly in neural stem cells (Fig. 3a). Tethering
assays were then performed with wild type UPF3B,
UPF3B-Ala423 and the UPF3B mutants from patients
by transfection of neural stem cells with the appropriate
plasmid combinations followed by induction of differen-
tiation for two days (Fig. 3b). The analysis by reverse
transcription followed by qPCR showed that Test Renilla
luciferase mRNA levels were reduced approximately
40-fold when wild type UPF3B was tethered compared to
when UPF3B-Ala423 was tethered. This was specific for
tethering of UPF3B as in reactions with Control Renilla
luciferase RNA, mean mRNA levels varied by only 7 %.
This indicates that differentiating neural stem cells
maintain the ability to perform UPF3B-promoted NMD.
Tethering of the mutant UPF3B proteins led to Renilla
luciferase mRNA levels between 10- and 20-fold higher
than with wild type UPF3B protein. These significant
effects on Renilla luciferase mRNA levels were caused by
binding of UPF3B proteins to the Test mRNA as in the
samples with Control Renilla luciferase mRNA the dif-
ferences in mRNA levels were small and means from three
independent experiments varied by only 35 %. Together
these experiments indicate that differentiating neural stem
cells are able to undergo UPF3B-promoted NMD, and that
NMD in these cells is sensitive to UPF3B protein variants
found in subjects with neurodevelopmental disorders.
Fig. 3 Mutations in UPF3B impair UPF3B protein NMD activity in neural stem cells. a. Expression of λN-HA-UPF3B proteins. Neural stem cells were
transfected with pCI-λN-HA-UPF3B expression constructs and protein expression was analysed 48 h after transfection by 10 % SDS PAGE followed
by detection by Western blotting. UPF3B proteins and α-tubulin were detected using anti-HA and anti-tubulin antibodies. b, c. Tethering assays.
b. Neural stem cells were transfected with the control plasmid phRL-TK, the reference plasmid phrGFP-C and the various pCI-λN-HA-UPF3B expression
constructs. 24 h after transfection, differentiation was induced. RNA was prepared 48 h after transfection and analysed by qPCR as described. c. Neural
stem cells were transfected, treated and mRNA levels analysed as in B except that phRL-TK was replaced with phRL-TK-10BoxB. For the graphs, Renilla
luciferase mRNA levels were standardised with respect to GFP mRNA levels, and Renilla luciferase mRNA levels in cells expressing UPF3B-Ala423 was
defined as 1. The graphs show average Renilla luciferase mRNA levels from three independent experiments, error bars indicate the standard deviation.
Asterisks indicate values significantly different from luciferase mRNA levels in the presence of UPF3B (one-way ANOVA followed by Dunnett's
test; P < 0.05)
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Missense mutations in UPF3B do not affect cellular
localisation in neurons
To determine whether the reduced activity of the UPF3B
proteins found in subjects with neurodevelopmental
disorders is linked to a restriction in cellular localisation we
expressed the various UPF3B proteins with an N-terminal
GFP tag in neural stem cells and analysed the localisation
of GFP-tagged proteins by confocal microscopy. In neurons
after six days of differentiation all UPF3B proteins were
detected in the somatic cytoplasm, in neurites and in the
nucleus (Fig. 4). Similar to the localisation of endogenous
UPF3B (Fig. 2), nuclear GFP-tagged UPF3B was enriched in
nucleoli and missense mutations in UPF3B did not signifi-
cantly alter the pattern of nuclear and nucleolar localisation
(Additional file 1: Figure S3). Thus the reduction of activity
in NMD caused by the mutations is not linked to an
obvious effect on cellular localisation. During these
experiments we noticed that the pattern of neurites
formed during differentiation appeared less complex in
cells expressing the mutant UPF3B GFP fusion proteins,
indicating that the expression of these proteins may have
an effect on neuronal differentiation.
Expression of UPF3B with missense mutations disturbs
neuronal differentiation of neural stem cells
We therefore wished to establish whether the expression
of the UPF3B protein variants found in patients with
neurodevelopmental disorders affects neuronal differenti-
ation. To avoid artefacts caused by the expression of the
UPF3B proteins fused to GFP we inserted the UPF3B pro-
tein open reading frames into pIRES-GFP, resulting in
constructs expressing UPF3B proteins and GFP separately
from a bicistronic transcript with an internal ribosome
entry site (IRES) located between the UPF3B and GFP
open reading frames. After transfection, cells were induced
to differentiate. Transfected cells were identified and
analysed by fluorescence microscopy after a further
three or six days. Examples of the appearance of neurons
transfected with the various constructs after six days
of differentiation are shown in Fig. 5a. While neurons
Fig. 4 Mutations in UPF3B do not affect its cellular distribution in neurons. Neural stem cells were transfected with the pEGFP-C3 expressing GFP
only (empty vector) or a pEGFP-C3 derivative expressing one of the UPF3B forms with an N-terminal GFP tag. Cells were diluted and re-plated
after 24 h, and then differentiated for 6 days prior to analysis by confocal microscopy. Shown are separate Z-stack projections of GFP and DAPI
channels and of the merged channels. The origin region of the enlarged section is indicated. The scale bar represents 20 μm
F5
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transfected with the empty vector pIRES-GFP and with
pIRES-GFP expressing UBP3B displayed a complex
branching pattern, this appeared much reduced in the
neurons expressing the mutant proteins. To quantify effects
on differentiation, neurite outgrowth was traced and
analysed using NeuronJ software. For this analysis, out-
growths directly from the soma were categorised as
primary neurites, while secondary and tertiary neurites
arising from primary neurites were categorised as
branches. These data are shown as box-and-whisker plots
Fig. 5 Expression of mutant UPF3B proteins affects neuronal differentiation of neural stem cells. Neural stem cells were transfected with
pIRES-GFP (empty vector) or pIRES-GFP derivatives expressing the indicated UPF3B proteins. Differentiation was induced after 24 h, and analysed
after 3 days and 6 days of differentiation by microscopy. Transfected cells were identified and visualised by GFP fluorescence. The analysis of
neuron differentiation was performed as described in Methods. a. Representative pictures of neurons with tracing, and tracing of 2 additional
neurons after 6 days of differentiation illustrating a reduction in branching in neurons expressing mutant UPF3B proteins. The scale bars represent
20 μm. Tracings are to scale with primary neurites traced with thicker lines then branches protruding from primary neurites. b, c. Branching was
analysed after 3 days and 6 days as described and results are presented as box plots. The box plots show the median, with boxes spanning
25th- 75th percentiles and the crossbars indicating the 10th and 90th percentiles. Experiments were done independently 3 times with similar
outcomes and the data were combined for presentation. Numbers of cells analysed are indicated. Asterisks indicate significantly reduced branching in
neurons expressing mutant UPF3B proteins compared to neurons transfected with the empty vector (Kruskal Wallis test followed by Dunn's multiple
comparison test; P < 0.05)
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in Fig. 5 and Additional file 1: Figure S4. There was no
significant difference in the numbers of primary neurites,
primary neurite length, branching and the length of the
branches between cells transfected with the empty vector
and cells expressing wild type UPF3B. This indicates that
expression of UPF3B protein did not have a significant
effect on neuronal differentiation. While the number of
primary neurites per cell was largely unaffected by the
presence of the mutant proteins we detected subtle differ-
ences in the length of primary neurites and of branches
that were however not statistically significant (Additional
file 1: Figure S4). In contrast, the number and complexity
of branches was reduced significantly in cells expressing
UPF3B proteins encoded by genes with mutations occur-
ring in neurodevelopmental disorders (Fig. 5). After three
days of differentiation, neurite branching in cells express-
ing these mutant UPF3B proteins was approximately two-
to three-fold reduced compared to cells transfected with
the empty vector, or the vector expressing wild type
UPF3B protein (Fig. 5). This effect increased with time,
leading to approximately a three- to six-fold reduction in
branching after six days of differentiation. In summary,
the expression of UPF3B proteins found in patients with
neurodevelopmental disorders, but not wild type UPF3B
protein, disturbs neuronal differentiation, specifically the
branching of neurites. This indicates that the expression
of these UPF3B proteins affects neuronal differentiation
and demonstrates that full UPF3B function is critical for
this process.
Functional NMD is important for neuronal differentiation
of neural stem cells
To determine whether the effect on neuronal differenti-
ation observed in Fig. 5 is compatible with a defect in
NMD we treated cells with the NMD inhibitor Amlexanox.
Lejeune and colleagues have shown that this compound is
able to inhibit UPF3B-induced mRNA decay but does not
act by inhibiting translation, a non-specific mechanism to
stabilise mRNAs [27]. Neural stem cells were differentiated
in the presence of Amlexanox, and for comparison in the
presence of the solvent DMSO or without any further
addition. Analysis of cells after three and six days of dif-
ferentiation revealed that the number of branches per cell
was reduced two-fold in the presence of Amlexanox
(Fig. 6a), similar to the effect of the expression of UPF3B
proteins encoded by genes with mutations occurring in
neurodevelopmental disorders (Fig. 5). In addition we ob-
served that treatment with Amlexanox caused a subtle but
significant reduction in the number of primary neurites per
cell and, after extended incubation, a reduction in branch
length (Additional file 1: Figure S5).
Next we wished to examine whether expression of
mutant UPF3B proteins affects NMD in neurons. We
transduced neural stem cells with lentivirus constructs
expressing wild type UPF3B protein and the mutant
forms UPF3B-Asp160 and UPF3B His-366 or the lenti-
virus backbone without any additional gene and subse-
quently induced differentiation. We decided to examine
the effect of UPF3B-Asp160 and UPF3B -His366 expres-
sion as representatives of proteins with mutations located
in the N-terminal and the C-terminal halves of UPF3B,
respectively. After six days of differentiation, total RNA
was isolated and the levels of Atf4, Arhgap24 and for com-
parison of Gapdh mRNA were determined. Both Atf4 and
Arhgap24 transcripts contain upstream open reading
frames (uORFs) which are classic features of mRNAs
regulated by the NMD process. Human and mouse
ARHGAP24 isoform 1 is encoded by mRNAs with
upstream open reading frames (uORFs) that are sub-
ject to nonsense-mediated decay [20]. Rat mRNA se-
quences GenBank:FQ225302, GenBank:CB582621 and
GenBank:CB609913 encode rat ARHGAP24 isoform 1. By
alignment of these mRNAs and human and mouse ARH-
GAP24 isoform 1 mRNAs with rat genomic DNA (RGSC
Genome Assembly 5.0) we identified a similar uORF in
the rat genome upstream of the annotated Arhgap24 gene
(chromosome 14 positions 8736874–8737122). ARH-
GAP24 isoform 1 mRNA is upregulated in subjects with
UPF3B mutations and overexpression of ARHGAP24 iso-
form 1 protein has been shown to affect neuronal branch-
ing [20]. Atf4 is a well-established target of NMD involved
in neuronal plasticity [28, 29]. Figure 6b shows that the
levels of both Atf4 and Arhgap24 isoform 1 mRNAs were
elevated in cells expressing UPF3B-Asp160 protein or
UPF3B His-366 protein compared to cells expressing
UPF3B or control-transduced cells. Arhgap24 also ex-
presses shorter isoforms lacking the N-terminal PH do-
main of ARHGAP24 isoform 1 and the uORF in the 5’
UTR. To examine whether the effect on Arhgap24 expres-
sion was limited to NMD substrates we measured expres-
sion using a qPCR assay able to detect all known and
predicted Arhgap24 transcripts. Using this assay we did
not observe a significant difference in Arhgap24 transcript
levels between cells expressing UPF3B-Asp160 protein or
UPF3B His-366 protein and cells expressing UPF3B or
control-transduced cells. This indicates that the expres-
sion of UPF3B-Asp160 protein or UPF3B His-366 pro-
teins specifically affects NMD targets. Together, these
observations indicate that the effects of the missense mu-
tations in UPF3B on neuronal development are caused by
an impairment of the NMD process.
Discussion
We have shown that UPF3B proteins with missense mu-
tations found in patients with autism, schizophrenia and
XLID are functionally impaired in NMD. We have used
tethering assays widely used to study the function of
NMD proteins to assess the ability of mutant UPF3B
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proteins from patients with these disorders to participate
in this process (Figs. 1 and 3). The activity of these
UPF3B proteins in NMD was reduced significantly, but
not inhibited fully. We performed this analysis in HeLa
cells and in HCN-A94 cells, a model for neuronal differ-
entiation. The results in these two cell types were similar
although there were differences in the extent of the
effects of specific mutations on the NMD process. It is
however difficult to directly compare these experiments
as levels in NMD factors in neurons are reduced upon
induction of differentiation (Fig. 2).
UPF1 in replicating neural stem cells was localised
mainly in the cytoplasm, as reported previously for other
cell types [24, 30] and remained so in differentiated neu-
rons (Fig. 2). UPF3B in undifferentiated and differenti-
ated neural stem cells was detected in both the nucleus
Fig. 6 A functional NMD pathway is important for neuronal differentiation. a. Treatment with NMD inhibitor Amlexanox affects neuronal
differentiation of neural stem cells. Neural stem cells were differentiated in the presence of DMSO or 10 μM Amlexanox or without any further
addition. Neurons were analysed 3 days and 6 days after induction of differentiation as described. Shown are representative pictures of neurons
with tracing, and tracing of 2 additional neurons after 6 days of differentiation illustrating a reduction in branching in Amlexanox treated neurons.
The scale bar represents 20 μm. Results are plotted showing the median, with boxes spanning 25th- 75th percentiles and the crossbars indicating
the 10th and 90th percentiles. Experiments were done independently 3 times with similar outcomes and the data were combined for presentation.
Numbers of cells analysed are indicated. The Asterisk indicates that branching of Amlexanox treated neurons is significantly reduced compared to
neurons differentiated without addition any addition or DMSO only (Kruskal Wallis test followed by Dunn's multiple comparison test; P < 0.05). b.
Expression of mutant UPF3B proteins that affect neuronal differentiation causes an increase in mRNA levels of selected NMD substrates. Neural stem
cells were transduced with lentivirus without insert (control) or expressing either UPF3B, UPF3B-Asp160 or UPF3B-His366 protein. 24 h after
transduction, differentiation was induced. RNA was isolated after six days of differentiation and gene expression was analysed by reverse
transcription followed by quantitative PCR. mRNA levels of NMD substrates Atf4 and Arhgap24 isoform 1, and of transcripts encoding all shorter
Arhgap24 isoforms not subject to NMD control were measured and standardised using Gapdh mRNA as reference. Atf4 and Arhgap24 mRNA
levels in cells transduced with the control virus were set as 1. Asterisks indicate values significantly increased compared to levels in cells transduced
with the control virus (one-way ANOVA followed by Dunnett's test; P < 0.05)
Alrahbeni et al. Molecular Brain  (2015) 8:33 Page 10 of 15
where it was enriched in nucleoli, and in the cytoplasm
(Fig. 2). Nucleolar localisation of UPF3 was observed in
plants, and human UPF3B was identified as a nucleolar
component by proteomic analysis [31, 32]. In HeLa cells,
UPF3B is localised to the nucleus and cytoplasm with
strong nuclear localisation, reflecting that UPF3B is a
nucleo-cytoplasmic shuttling protein that performs its
function in NMD in the cytoplasm [24, 33, 34]. The
UPF3B localisation patterns observed in the brain is
more complex and changes during development [21].
For example, UPF3B is being largely excluded from the
nucleus in neural progenitor cells during early stages of
mouse embryonic development while at later stages
the protein clearly localises to the nucleus in the same
cell type.
We observed that the levels of NMD factors UPF1 and
UPF3B are down-regulated during neuronal differenti-
ation of neural stem cells (Fig. 2), similar to observations
by others in mouse neural stem cells [21, 35]. Down-
regulation of UPF1 and concomitant reduction of NMD
activity was linked to changes in gene expression favour-
ing neuronal differentiation of mouse neural stem cells,
providing a paradigm for the role of the NMD process
during neuronal differentiation [35].
Using GFP-tagged UPF3B proteins we showed that
cellular localisation was not affected by the mutations
(Fig. 4 and Additional file 1: Figure S3), in agreement
with a previous analysis of the localisation of UPF3B-
His366 and UPF3B-Gln355 in primary neurons [3]. This
indicated that the effect of the missense mutations on
NMD was not due to a change in cellular localisation of
UPF3B proteins.
Our findings indicate that UPF3B protein, through its
function in NMD, is important for neuronal differenti-
ation. The neuronal differentiation of neural stem cells
was disturbed by the expression of UPF3B proteins from
patients with neurodevelopmental disorders. Specifically
the branching of neurites was reduced significantly (Fig. 5).
This can be linked to a defect in NMD; treatment of cells
with the NMD inhibitor Amlexanox similarly affected
neurite branching, and the expression of two mutant
UPF3B proteins, UPF3B-Asp160 and UPF3B-His366, led
to a subtle but significant increase of the expression of the
NMD substrates Atf4 and Arhgap24 (Fig. 6). Arhgap24 is
of particular interest as aberrant expression of Arhgap24
in primary hippocampal neurons has been shown to cause
a reduction of neuronal arborisation [20]. The observation
that X chromosome inactivation in female carriers in fam-
ilies with UPF3B missense mutations is skewed towards
inactivation of the chromosome carrying the UPF3B locus
with the mutations is compatible with that the expression
of these proteins may be detrimental [2, 3].
It will be interesting to explore how the mutations in
UPF3B would affect UPF3B activity. The four mutations
we analysed are not in one of the regions known to be
important for UPF3B function; the RNP motif (Fig. 1,
amino acids 52–137) and the exon junction complex
interaction domain (amino acids 421–434), instead
they are located between these two elements (Fig. 1,
Additional file 1: Figure S1). Structural information is
available for the UPF3B N-terminus and the C-terminus
with the exon junction complex interaction domain, but a
complete structure encompassing the regions containing
the mutations is to our knowledge not currently available
[16, 19]. We are therefore unable to make predictions
about the effects of the mutations on UPF3B protein
structure. However it is possible that these mutations, by
changing the secondary or tertiary structure of UPF3B
protein, affect the function of the domains involved in
protein-protein interaction with UPF2 protein and the
EJC, respectively. Interestingly in patients expressing
UPF3B-Asp160, UPF3A is up-regulated similar to the situ-
ation in cells from patients that lack UPF3B expres-
sion [13, 20]. As UPF3A protein levels are controlled
and kept low by competition with UPF3B for binding
to UPF2 this suggests that the replacement of Tyr160
by Asp in UPF3B protein may attenuate the UPF3B-
UPF2 interaction.
Post-mortem studies and mouse models have linked
neurodevelopmental disorders to the complexity of
neuronal branching. Decreased dendritic complexity of
cortical neurons has been demonstrated post-mortem in
schizophrenia [36, 37]. Post-mortem examination of
neurons from patients with Rett syndrome revealed
structural changes including a reduction in dendrites of
cortical neurons [38]. Reduced complexity of dendrites
has been observed also for hippocampal neurons of a
mouse model for Rett syndrome and for cortical neurons
in a mouse model for Timothy syndrome [39, 40]. Our
findings implicate UPF3B and the NMD pathway in the
control of dendrite complexity.
In conclusion, our observations indicate that despite
the down-regulation of NMD factors during neuronal
differentiation in neural stem cells, fully functional
NMD machinery is critical for appropriate differenti-
ation. Missense mutations in UPF3B found in patients
with neurodevelopmental disorders may contribute to
the development of these disorders by an impairment of
UPF3B activity in the NMD process that results in aber-
rant gene expression affecting neuronal differentiation.
Normalisation of NMD might be a route to ameliorate
the phenotype. Inhibition of NMD is being considered
as strategy to treat genetic diseases caused by non-
sense mutations, possibly in combination with com-
pounds such as Ataluren that facilitate the read through
of nonsense codons by the ribosome [41]. This approach
may impact on the development and function of neu-
ronal networks as inhibition of nonsense-mediated
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decay is likely to interfere with the expression control




HeLa cells were maintained in DMEM media supple-
mented with 10 % fetal bovine serum. HCN-A94 adult
rat hippocampal neural stem cells were obtained from
Fred Gage (Salk Institute, La Jolla, CA, USA) and were
maintained as described [25] in DMEM/F12 medium
with N2 supplement and 20 ng/ml FGF-2 (Peprotech).
Neuronal differentiation was induced in DMEM/F12
medium with N2 supplement (Life Technologies) and
with 1 μM retinoic acid and 5 μM forskolin [26]. All
cells were cultivated at 37 °C in a 5 % CO2 atmosphere.
Amlexanox (Tocris Bioscience) was dissolved in DMSO
and applied to cells together with retinoic acid and
forskolin.
Nucleic acids
pGL3-promoter expressing firefly luciferase was from
Promega and phrGFP-C was from Stratagene/Agilent.
Plasmids pCI-λNhUPF3B and pCI- λNhUPF3BArg423Ala
expressing the human UPF3B isoform 2 (GenBank:NP_
075386) and the UPF3BArg423Ala protein were a
generous gift of Niels Gehring (University of Cologne,
Germany) [18]. An HA tag was introduced into these
plasmids in the XhoI site between the λN and UPF3B
domains, producing pCI-λN-HA-UPF3B and pCI-λN-
HA-UPF3B-Ala423. Other mutations were introduced
into pCI-λN-HA-hUPF3B by site-directed mutagenesis
using the QuikChange Lightning Site-Directed Mutagen-
esis Kit (Agilent Technologies). This resulted in plasmids
pCI-λN-HA-UPF3B-Asp160, pCI-λN-HA-UPF3B-Lys225,
pCI-λN-HA-UPF3B-Gln355, pCI-λN-HA-UPF3B-His366
and pCI-λN-HA-UPF3B-Ala423, respectively. Sequences
are available on request. UPF3B fragments were excised
from the pCI-λN-HA plasmids using XhoI and SalI and
inserted into pEGFP-C3 (Clontech Laboratories) plasmid
cleaved with the same enzymes. This resulted in plasmids
pEGFP-UPF3B, pEGFP-UPF3B-Asp160, pEGFP-UPF3B-
Lys225, pEGFP-UPF3B-Gln355, UPF3B-His366 and
pEGFP-UPF3B-Ala423. The UPF3B open reading frame
was amplified from pCI-λN-HA-N-UPF3B plasmid using
primers with BamHI and XhoI restriction sites. The
amplicon was inserted into pGEM-Teasy (Promega)
and then released using BamHI and XhoI and inserted
into pIRES-AcGFP1 (Clontech Laboratories; abbreviated
pIRES-GFP) cleaved with the same enzymes. Mutations
were introduced into UPF3B by site-directed muta-
genesis as described, producing plasmids pIRES-UPF3B-
GFP, pIRES-UPF3B-Asp160-GFP, pIRES-UPF3B-Lys225-
GFP, pIRES-UPF3B-His366-GFP and pIRES-UPF3B-
Ala423-GFP. UPF3B fragments were amplified from
pEGFP constructs and inserted into the EcoRI site
of pCDH-EF1-MCS-IRES-GFP (Systems Biosciences,
Mountain View, CA, USA) by In-Fusion cloning (Clontech
Laboratories). phRL-TK-10BoxB was produced by releas-
ing the 5BoxB element located in the 3’ untranslated
region of in pRL-TK-5BoxB [42] using an XbaI digest and
replacing it with an element containing 10BoxB repeats.
All plasmids constructions were confirmed by Sanger
dideoxy sequencing.
Tethered function assays
For luciferase activity assays, HeLa or HCN-A94 cells
were grown in 24 well plates and transfected with 0.1 μg
phRL-TK-10BoxB plasmid, 0.1 μg of pGL3 promoter plas-
mid and with 0.7 μg of one of the six pCI-λN-HA-tagged
UPF3B expression constructs. For mRNA analysis by
qPCR, HeLa or HCN-A94 cells grown in 35 mm plates
were transfected with 0.5 μg phRL-TK-10BoxB plasmid,
0.5 μg of phrGFP plasmid and 5 μg of one of the six pCI-
λN-HA-UPF3B expression constructs. Transfections were
done using either GeneTran™ (Biomiga), or Lipofectamine
2000™ (Life Technologies). Each transfection was done
in triplicate, and each experiment was done at least
three times. Transfections into HeLa cells were ana-
lysed after 48 h. HCN-A94 cells were induced to dif-
ferentiate 12–24 h after transfection and were analysed
after a further 48 h. Luciferase activity was analysed using
the dual luciferase reporter assay system and a GloMaxR
Luminometer (Promega). Total RNA was prepared using
the Biomiga Tissue RNA Mini Kit. Samples were treated
with DNase I according to the manufacturer’s instruc-
tion. cDNA synthesis was done using Superscript II
reverse transcriptase (Life Technologies) and random
hexamer primers (Bioline, London, UK). Quantitative
PCR (qPCR) reactions were performed in a Roche Light-
Cycler 480 qPCR system with Universal ProbeLibrary
assays (Additional file 1: Table S1).
Analysis of neuronal differentiation
HCN-A94 cells were grown in 6 well plates and
transfected with pEGFP-UPF3B constructs or pIRES-
UPF3B-GFP constructs. After 24 h, cells were diluted
and transferred into 24 well plates. After a further
24 h, differentiation was induced. Live cell images were
taken using an Axiovert 40CFL microscope with Axio
Vison software (Zeiss). Pictures were converted into gray-
scale Tiff files and analysed using ImageJ software with
NeuronJ plugin to trace cells [43]. Neurites protruding
directly from the soma were classified as primary neurites.
Secondary and tertiary neurites originating from neur-
itic processes and ending at a terminus were classified
as branches.
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Protein localisation
For the localisation of GFP-UPF3B fusion proteins
HCN-A94 cells were seeded in 6-well plates and the fol-
lowing day were transfected with 5 μg of pEGFP-C3 or
derivatives expressing GFP-UPF3B fusion proteins using
Lipofectamine 2000 as per manufacturer’s instructions.
The following day cells were diluted in 35 mm μ-Dishes
(Ibidi) and grown for 48 h or differentiated for six days.
The medium was removed and cells were fixed in PBS/
4 % paraformaldehyde for 10 min at room temperature
and washed three times with PBS for 5 min. Cell nuclei
were stained with DAPI for 5 min and then washed
three times with PBS.
For detection of endogenous UPF3B and UPF1 proteins
cells were fixed in ice-cold 100 % methanol at −20 °C
for 15 min and washed three times in PBS for 5 min.
Non-specific interactions were incubated with 5 %
normal goat serum (Sigma-Aldrich) in PBS with 0.3 %
Triton X-100 for staining with anti-UPF3B antibody
staining and with 10 % BSA in PBS with 0.3 % Triton
X-100 for staining with anti-UPF1 antibody for 1–2 h.
Cells were stained with rabbit anti-UPF3B (Abgent)
or goat anti-RENT1 (UPF1) (Bethyl Laboratories)
antibodies in 1x PBS, 1 % BSA, 0.3 % Triton X-100
overnight at 4 °C. Then cells were washed three times
in PBS and probed with goat anti-rabbit AlexaFluor
555 or donkey anti-goat AlexaFluor 488 (Life Tech-
nologies) diluted in antibody solution for 1 h and
then washed three times with PBS. Cells were counter-
stained with DAPI for 5 min and washed three times
with PBS.
For detection of Fibrillarin and UPF3B, cells were fixed
in 4 % paraformaldehyde in PBS, washed three times
with PBS and permeabilized in 0.1 % Triton X-100.
Following 1 h blocking in 5 % normal goat serum
(Sigma-Aldrich) in PBS with 0.3 % Triton X-100 cells
were incubated with mouse anti-Fibrillarin antibody
(1:500; Abcam) overnight at 4 °C in 1x PBS, 1 % BSA,
0.3 % Triton X-100. The next day cells were washed three
times with PBS and incubated with goat anti-mouse Alexa
Fluor 594 (Invitrogen) in 1x PBS, 1 % BSA, 0.3 % Triton
X-100. After 1 h, cells were then washed three times with
PBS, blocked for 1 h and incubated with anti-UPF3B
(1:400, Abgent) in in 1x PBS, 1 % BSA, 0.3 % Triton X-
100 overnight at 4 °C. Then cells were washed three times
with PBS and incubated with goat anti-rabbit Alexa Fluor
888 (1:400, Invitrogen). After 1 h cells were washed three
times with PBS, counterstained with DAPI and washed
again three times with PBS. Images were captured using
an inverted confocal microscope (Zeiss LSM 710) with
63x oil objective and analysed using ZEN (Zeiss) and
ImageJ software [43]. Microscopy was performed in the
Microscopy and Histology Core Facility at the University
of Aberdeen.
Western blotting
Proteins were separated using 8 % or 10 % SDS poly-
acrylamide gel electrophoresis. Proteins were transferred
onto Hybond P membrane (GE Healthcare) and detected
using either a mouse monoclonal anti-HA antibody
(HA.11, Covance), a mouse monoclonal anti-α-tubulin
antibody (Sigma-Aldrich), a polyclonal goat UPF1 anti-
body (Bethyl Laboratories), an affinity-purified rabbit
polyclonal UPF3B antibody (Abgent), a mouse mono-
clonal GAPDH antibody (Pierce) or a rabbit monoclonal
β-III Tubulin antibody (Cell Signaling Technology).
Horseradish peroxidase coupled secondary anti-mouse
and anti-rabbit antibodies were from Cell Signaling
Technology and horse radish peroxidase coupled secon-
dary anti-goat antibodies from Santa Cruz Biotechnology.
Proteins were detected using ECL or ECL plus chemi-
luminescence reagents (GE Healthcare) and visualised
using X-ray film and developed using an X-Omat
processor (Kodak) or using a Thermo Scientific My
ECL imager. The images produced were analysed
using ImageJ software or Image Studio Lite software
(LI-COR Biosciences).
Analysis of NMD by qPCR
Lentivirus particles were produced by transfection of
HEK-293 T cells with pCDH-EF1-MCS-IRES-GFP and
UPF3B expressing derivatives together with helper plas-
mid mix pPACKH1 (System Biosciences). After 2 days,
virus-containing supernatants were collected and applied
to neural stem cells and after a further 24 h, differentiation
was induced. Total RNA was prepared using a Purelink
RNA kit with DNAse treatment (Life Technologies).
cDNA synthesis was done using Superscript II reverse
transcriptase (Life Technologies) and oligo-dT primers
(Promega). Quantitative PCR (qPCR) reactions to de-
tect Gapdh, Arhgap24 and Atf4 mRNAs were per-
formed using a LightCycler 480 qPCR system with
Universal ProbeLibrary assays (Roche) (Additional file 1:
Table S1). ARHGAP24 isoform 1 (Swiss-Prot:Q5U2Z7)
encoding transcripts were identified by blast search. The
qPCR assay specifically detects the region encoding the
ARHGAP24 isoform 1 N-terminal PH domain repre-
sented by Arhgap24 mRNAs GenBank:CB582621 and
GenBank:CB609913. A second Arhgap24 assay detects
transcripts encoding ARHGAP24 isoform 1, the shorter
isoform encoding GenBank:NP_001012032 and pre-
dicted transcripts encoding related isoforms lacking
the PH domain.
Additional file
Additional file 1: Supplemental Figures S1-S5, supplemental Table
S1 and supplemental Methods.
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